VANCOUVER, July 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI - News; TSX: QLT - News; “QLT” or the “Company”) today announced encouraging interim data from an ongoing Phase II clinical trial and a device study for the punctal plug delivery system. These studies are part of a development program that is being conducted by QLT’s wholly-owned subsidiary, QLT Plug Delivery, Inc.
